In a pioneering move to enhance patient care for fibrosing lung disease in the United States, Brainomix, a leader in AI imaging solutions, has entered into a partnership with Boehringer Ingelheim. This collaboration aims to leverage advanced technology to expedite diagnosis and improve treatment accessibility for patients suffering from this debilitating condition.
Brainomix’s e-Lung software will play a pivotal role in this initiative. The software, which has received clearance from the FDA, is designed to analyze routine CT scans, providing vital insights that can lead to quicker and more accurate diagnoses. This is especially crucial for pulmonary fibrosis, a progressive and often fatal disease, where early detection can significantly impact patient survival rates.
The partnership’s strategy includes deploying the e-Lung software across top pulmonology centers in the US. This deployment aims to validate the software’s effectiveness and help streamline care pathways, making it easier for patients to receive timely and appropriate treatment. Dr. Michalis Papadakis, CEO of Brainomix, highlighted their expertise in stroke network technology as a foundation for their approach to lung disease care.
Boehringer Ingelheim and Brainomix Partner to Revolutionize Fibrosing Lung Disease Diagnostics with e-Lung Software
Ioannis Sapountzis of Boehringer Ingelheim emphasized the transformative potential of the e-Lung software in the realm of diagnostics. By utilizing digital technology, the partners aim to not only revolutionize the way lung diseases are diagnosed but also significantly enhance patient outcomes. This collaboration underscores a shared commitment to leveraging cutting-edge technology to drive better health results.
Key takeaways from this collaboration include:
- Accelerated diagnosis through advanced AI imaging technology.
- Enhanced access to treatment for patients with fibrosing lung disease.
- Streamlined care pathways at leading US pulmonology centers.
- Potential for improved patient survival rates with earlier detection.
- Validation of the e-Lung software’s efficacy in real-world clinical settings.
This partnership between Brainomix and Boehringer Ingelheim is poised to make substantial strides in the care of fibrosing lung disease. By integrating Brainomix’s state-of-the-art e-Lung software into routine clinical practice, the initiative aims to significantly reduce the time to diagnosis and ensure that patients receive timely and effective treatment. As this collaboration progresses, it stands as a testament to the transformative power of digital technology in healthcare, offering hope for improved outcomes for those affected by pulmonary fibrosis.
Brainomix and Boehringer Ingelheim Partner to Enhance Fibrosing Lung Disease Care with e-Lung Imaging Software
The project will evaluate the real-world impact of Brainomix’s e-Lung imaging software to improve the identification and access to treatment for people with progressive pulmonary fibrosis in the US. Brainomix, a pioneer in artificial intelligence (AI) imaging solutions, has announced it has entered into a partnership with German pharmaceutical company Boehringer Ingelheim for a collaborative program of activity to improve the care of patients with fibrosing lung disease in the US.
This landmark project will focus on the opportunity for AI imaging analysis using Brainomix 360 e-Lung on routine CT scans to accelerate the diagnosis and improve access to treatment for people living with fibrosing lung disease.
Pulmonary fibrosis is a chronic lung condition that is progressive and life-limiting. Untreated, patients can have a lifespan as short as 5 years from diagnosis, and yet despite this, often wait up to 2 years for diagnosis. The key to the best survival for patients with fibrosing lung disease is the earliest initiation of treatment, but identifying patients eligible for treatment based on imaging can be challenging, even for experts.
Through this partnership, Brainomix will deploy its FDA-cleared e-Lung software to leading US pulmonology centers and their networks of referring sites. The data generated will validate the value of e-Lung, highlighting the potential of digital technology to optimize pathways of care and improve outcomes for people with fibrosing lung disease, a vision shared between Brainomix and Boehringer Ingelheim.
Brainomix and Boehringer Ingelheim Partner to Revolutionize Fibrosing Lung Disease Diagnosis and Treatment
Dr. Michalis Papadakis, CEO and Co-Founder of Brainomix said: “There is an urgent need to improve the identification of people with fibrosing lung disease. This will enable earlier access to specialist care and the opportunity for faster initiation of treatment, which can slow the worsening of the disease. The patient pathway for people with fibrosing lung disease is currently fragmented and it can take many years for a patient to be diagnosed.”
“This partnership enables us to leverage our established experience and expertise connecting stroke networks to develop a similar network model of care for patients with fibrosing lung disease, generating real-world evidence that will drive the opportunities we have with e-Lung to help improve outcomes for patients and their families.”
Ioannis Sapountzis, Head of Global Therapeutic Areas at Boehringer Ingelheim said: “At Boehringer Ingelheim, we know how critical early and confident detection of progression is for people living with fibrosing lung disease. We believe that Brainomix 360 e-Lung has the potential to revolutionize the diagnostic landscape and thereby enable earlier treatment decisions at a pivotal stage of the patient’s journey. This can ultimately improve patient outcomes and quality of life of those affected.”
Brainomix 360 e-Lung received FDA clearance in May 2024, the same month the company announced a series of new studies highlighting the prognostic value of its lung imaging biomarkers in patients with fibrotic lung disease. The studies, presented at the American Thoracic Society (ATS) Conference in San Diego, reflect the company’s expanding Life Sciences partnerships and academic collaborations with luminary research centers in the lung space.
Resource: PR Newswire, July 18, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
